Trump EPA Moves to Repeal Ethylene Oxide Rules, Leaving Millions Near Sterilization Plants at Risk

The Environmental Protection Agency under the Trump administration is moving to repeal regulations on ethylene oxide, a colorless, odorless gas that the agency itself classifies as a known human carcinogen. The rollback would loosen emission standards for roughly 90 commercial sterilization facilities scattered across American neighborhoods, facilities that use the chemical to sterilize medical equipment and supplies. For the communities living downwind of those plants, the decision is not an abstraction. It is a recalibration of how much cancer risk the federal government is willing to impose on them without their consent.

Ethylene oxide has been used in industrial sterilization for decades, and its effectiveness is not in dispute. What is in dispute, apparently, is how seriously the government should take its dangers. The EPA's own assessments have long flagged the chemical as extraordinarily potent, far more so than previously understood. A 2016 reassessment by the agency's Integrated Risk Information System found that ethylene oxide is roughly 30 times more carcinogenic than previously estimated, with particular concern around breast cancer and lymphoma risks from long-term, low-level exposure. That finding set off years of regulatory pressure that eventually produced the rules now on the chopping block.

The facilities in question are not remote industrial parks. Many are embedded in residential areas, often in communities that already carry disproportionate environmental burdens. Investigative reporting by ProPublica in 2018 helped bring national attention to the issue, mapping cancer risk from industrial air toxics across the country and showing that ethylene oxide emissions were among the most significant contributors to elevated risk in specific zip codes. The communities most exposed were frequently lower-income and disproportionately Black and Latino, a pattern that fits the broader geography of environmental injustice in the United States.

The Biden administration finalized stricter emission standards for these facilities in 2024, tightening limits on how much ethylene oxide plants could release and requiring enhanced monitoring and controls. Industry groups pushed back hard, arguing the rules were technically infeasible and economically damaging. The sterilization sector warned that overly strict regulation could disrupt the supply of sterile medical devices, a concern that carries real weight given how dependent hospitals are on a steady flow of sterilized equipment. That argument gave political cover to those seeking to roll back the rules, framing the choice as one between cancer risk and healthcare access rather than between corporate compliance costs and public health.

But that framing obscures a more complicated reality. The sterilization industry had years of advance notice that stricter standards were coming, and many facilities had already begun investing in engineering controls and alternative technologies. Repealing the rules now does not simply freeze the status quo. It actively removes the regulatory pressure that was driving those investments, potentially locking in higher emission levels for years to come. The second-order consequence here is significant: if facilities that had begun transitioning to safer practices now have no regulatory reason to complete those transitions, the communities nearby bear the cost of that reversal in the form of continued exposure.

There is also a legal dimension worth watching. Environmental and public health groups are virtually certain to challenge the repeal in court, and the EPA's own scientific record on ethylene oxide makes the agency's position legally precarious. Courts have increasingly scrutinized regulatory rollbacks that contradict an agency's own prior scientific findings, and the 2016 carcinogenicity reassessment is a substantial piece of evidence that any repeal will have to contend with. The litigation could drag on for years, creating a prolonged period of regulatory uncertainty that itself has costs, both for communities seeking protection and for industries trying to plan capital investments.

Meanwhile, states are not waiting. California, Illinois, and other states with significant concentrations of sterilization facilities have moved to impose their own stricter standards, and that patchwork approach is likely to accelerate if federal protections weaken. The result could be a two-tier system in which residents of states with strong environmental agencies receive meaningful protection while those in states with weaker oversight are left exposed, a dynamic that deepens rather than resolves the underlying inequity.

The deeper question the ethylene oxide fight raises is one about how the United States values the health of people who live near industrial facilities versus the economic interests of the industries operating them. That question has never been cleanly resolved, and the current rollback suggests it is being answered, at least for now, in a particular direction. Whether courts, states, or future administrations reverse that answer remains to be seen, but the communities living closest to these plants will be breathing the consequences of this decision long before any of those processes conclude.